Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells <i>in vitro</i>.

Peters, Godefridus J; van Gemert, Frank P A; Kathmann, Ietje; Reddy, Guru; Cillessen, Saskia A G M; Jansen, Gerrit

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro.

Peters, Godefridus J; van Gemert, Frank P A; Kathmann, Ietje; Reddy, Guru; Cillessen, Saskia A G M; Jansen, Gerrit.

Afiliação

Peters GJ; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, Netherlands.
van Gemert FPA; Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
Kathmann I; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, Netherlands.
Reddy G; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, Netherlands.
Cillessen SAGM; Spectrum Pharmaceuticals, Irvine, CA, United States.
Jansen G; Department of Pathology, Amsterdam UMC, VU University Medical Center Amsterdam, Amsterdam, Netherlands.

Front Cell Dev Biol ; 8: 577215, 2020.

Article em En | MEDLINE | ID: mdl-33163492

Palavras-chave

antifolates; belinostat; diffuse B-cell lymphoma; histone deacetylase inhibitors; peripheral T-cell lymphoma; pralatrexate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Cell Dev Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google